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Abstract
The association between cumulative inflammatory burden and increased cardiovascular
(CV) risk in patients with immune-mediated inflammatory rheumatic disorders, particularly
rheumatoid arthritis (RA), is widely recognized. Furthermore, the complex and dynamic
interrelation between traditional cardiovascular risk factors, systemic inflammation, early
accelerated atherosclerosis, and RA-related factors remains a challenge in routine practice.
New European League Against Rheumatism (EULAR) 2016 recommendations have recently
highlighted three key trends in cardiovascular risk assessment and management in patients
with RA including optimal disease control (early diagnosis, treat-to-target strategy with the
dynamic use of antirheumatic synthetic and biologic drugs) and non-pharmacological as
well as pharmacological management of risk factors. The present chapter will emphasize
excessive cardiovascular morbidity in RA, the optimal strategy to identify and stratify the
cardiovascular risk profile, the prime selection of medication from the whole spectrum of
non-biologic and biologic (TNF and non-TNF) drugs according to their cardiotoxicity.
Keywords: cardiovascular burden, rheumatoid arthritis, inflammation, TNF inhibitors,
tocilizumab
1. Introduction
The association between cumulative inflammatory burden and increased cardiovascular (CV)
risk in patients with immune-mediated inflammatory rheumatic disorders, particularly rheu-
matoid arthritis (RA), is widely recognized [1–5].
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Furthermore, the complex and dynamic interrelation between traditional CV risk factors (such
as hypertension, diabetes, obesity, abnormal lipid metabolism), chronic systemic inflamma-
tion, early accelerated atherosclerosis, and RA-related factors (e.g., C-reactive protein level,
CRP, disease activity and severity, medication) taken together in a genetically predisposed
background remains a challenge in routine practice [1–5].
European League Against Rheumatism (EULAR) 2015/2016 recommendations for cardiovas-
cular disease management have recently highlighted three key trends in cardiovascular risk
assessment and management in patients with RA and spondyloarthropathies (ankylosing
spondylitis, psoriatic arthritis) including optimal disease control (early diagnosis, treat-to-
target strategy with the dynamic use of antirheumatic synthetic and biologic drugs) and non-
pharmacological as well as pharmacological management of risk factors [6, 7].
The present chapter will emphasize excessive cardiovascular morbidity in RA, the optimal
strategy to identify and stratify the cardiovascular risk profile in different RA settings, the
prime selection of medication from the whole spectrum of non-biologic (methotrexate and
non-methotrexate drugs) and biologic (TNF and non-TNF) antirheumatic drugs according to
their cardiotoxicity.
2. Cardiovascular risk in patients with RA
2.1. Cardiovascular burden in RA
Patients with systemic autoimmune conditions especially inflammatory joint disorders such as
RA are at increased risk to develop cardiovascular comorbidity, in particular subclinical or
clinically significant atherosclerotic coronary heart disease [1–5, 8].
Compared to general population, patients with RA experience excessive cardiovascular mor-
bidity and, even, mortality, with an increased risk of about 50% [1, 2, 8, 9]. The rate of global
cardiovascular as well as individual events comprising fatal and nonfatal myocardial infarc-
tion, congestive heart failure, stroke, and major adverse cardiac events (MACE) is increased in
RA, the magnitude of cardiovascular risk in such patient being comparable with that related to
diabetes [1, 2, 8].
A comprehensive overview of cardiovascular complications and safety issues indicates that
RA develops twice myocardial infarction and features an increased risk (up to 87%) of heart
failure as compared to general, non-RA population [1–3, 8–11]. Moreover, congestive heart
failure in different RA subtypes has a worsen prognosis compared to non-RA patients; more
than half of patients known with RA are prone to undergo diastolic heart failure, while
diastolic ventricular failure and pulmonary arterial hypertension are broadly reported in
long-standing RA [2, 8–11]. Myocarditis typically associates with active disease subtypes and
is rare, clinically non-symptomatic, without influence on cardiac mortality [1, 2]. Conversely,
atherothrombosis and clinically significant coronary heart disease are highly expressed (65%
increase in cardiovascular risk) and account for premature death [2]. Finally, valvular disease,
especially mitral regurgitation, is frequent (80%) but usually asymptomatic, while valve nod-
ules, conduction anomalies, and arrhythmias are uncommon in such patients [2].
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Both early RA and established or long-standing RA are characterized by augmented CV risk,
with a special emphasis on active status, irrespective of disease duration [1, 2, 4, 11].
Cardiovascular comorbidities of autoimmune disorders are the result of different contributing
factors and their synergistic effects [1, 2, 4, 5, 8, 9, 11]. Although the prevalence and influence of
traditional risk factors in RA is high, the excess of cardiovascular burden is only partially
clarified [1–4, 6, 8, 9, 11]. A wide spectrum of nontraditional meaning RA-associated factors is
already considered, including disease activity, severity, as well as antirheumatic drugs [1, 2, 4,
6, 8, 11–13].
2.2. Factors involved in cardiovascular risk in RA
The dynamic link between chronic systemic inflammation and atherosclerosis remains a key
point in the pathobiology of cardiovascular involvement in various systemic autoimmune
conditions, including inflammatory rheumatic disorders [1, 2, 10–13].
Cardiovascular risk in RA is multifactorial; since traditional risk factors fairly explain, specific
issues related to disease activity and medication endorses the cardiovascular disease in RA
[1–4, 10–13].
Smoking, diabetes, obesity, hypertension, as well as abnormal lipid pattern (dyslipidemia) are
major metabolic risk factors for cardiovascular disease, while seropositivity (rheumatoid factor,
RF, and anti-cyclic citrullinated peptide antibodies (ACPA)), systemic extra-articular features,
anti-inflammatory (nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids), and
disease-modifying antirheumatic drugs (DMARDs) are specific aspects with precise relevance
for cardiovascular outcomes in RA patients (Figure 1) [1, 2, 4–6, 10–13].
Figure 1. Traditional and non-traditional cardiovascular risk factors in RA (adapted from 8).
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Furthermore, it is well established that chronic inflammation represents an independent risk
factor for premature atherosclerosis, irrespective of other traditional factors [1, 3, 4], supporting
severe, either subclinical or clinical coronary, and carotid disease in patients with RA [10–13].
Inflammation may alter the effect of existing risk or protective factors for cardiovascular
disease, leading to an altered cardiovascular profile [1, 2, 6, 10–13].
Potent pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin
(IL)-6 and their signaling pathways play a fundamental role in persistent systemic inflamma-
tion and are the main determinants of cardiovascular risk in RA [1–4, 6]; in addition, they may
interfere with classic factors resulting in altered endothelial function, insulin resistance, mod-
ified lipid spectrum, and the obesity paradox in RA [1, 2, 10–14].
There is a body of evidence showing the proatherogenic role of TNF-α and IL-1 as well as
potential dual effect of IL-6 on atherogenesis [2, 3].
Thus, targeting inflammation to reduce the cardiovascular disease risk in inflammatory condi-
tions seems to be a realistic project; additionally, an optimal control of rheumatoid inflamma-
tion through specific synthetic and/or biologic antirheumatic drugs always underwrites the
decline of cardiovascular comorbidity [1–3, 6, 7].
The exclusive relationship of inflammation, endothelial dysfunction, and surrogate biomarkers
of atherosclerosis with risks to cardiovascular disease among RA patients was extensively
addressed [1–3, 10–13]. The pathophysiology of endothelial dysfunction is multifactorial, a
complex network of interacting factors and mechanisms being emphasized. Not only different
metabolic (dyslipidemia, hyperglycemia), non-metabolic (hypertension, smoking, oxidative
stress) but also RA-specific factors (systemic inflammation) are associated with vascular dys-
function [1, 2, 9, 15–21].
Early intervention of irreversible vascular damage is strictly related to abnormal vascular tone,
upregulation of fibrinolysis, and coagulation systems with subsequent procoagulant imbal-
ance, subclinical and clinical atherosclerosis, and supporting cardiovascular disease develop-
ment in RA (Figure 2) [1, 2, 6, 9–13].
2.2.1. Traditional risk factors
Although the relation between traditional cardiovascular risk factors and RA was largely
addressed in the last decade, conflicting effects are still open [1–3, 9]. Obviously, classic factors
mapping cardiovascular outcomes are more common among patients with autoimmune dis-
orders [1, 2, 9].
A closer look to various traditional risk factors for cardiovascular disease in RA, their preva-
lence, and relations with disease activity and severity revealed the following aspects (Table 1).
2.2.1.1. Smoking
Recognized as a risk factor of both autoimmune diseases and accelerated atherosclerosis [1, 2,
15], tobacco smoking is able to modulate the immune system (e.g., induction of the inflammatory
Newest Updates in Rheumatology88
responses and apoptosis, cytokine imbalance, DNA damage), to alter endothelial cells (e.g.,
overexpression of adhesion molecule, endothelial dysfunction), and to promote a procoagulant
and inflammatory environment [1, 3, 15].
Smoking has a high prevalence in patients with RA and is classically associated with different
predictive factors of the cardiovascular outcomes including seropositivity (for both RF and
ACPA), disease severity, disability, and articular damage (erosions) [1, 2, 15]. Various studies
have suggested that smoking and second-hand (passive) smoking may limit the therapeutic
response in RA, promoting and perpetuating inflammatory aggressive effects on cardiovascu-
lar risk [1–3, 6, 15].
2.2.1.2. Hypertension
Among classical risk factors, hypertension is an important predictor of cardiovascular events
not only in general population but also in patients with systemic autoimmune conditions, with
the highest morbidity in RA (up to 40% in CORRONA) [1, 9, 16].
Since the pathobiology of increased blood pressure is multifactorial, blood pressure control in
inflammatory autoimmune settings is largely related to chronic inflammation and immune-
mediated mechanisms, along with classic mechanical injury of the arterial wall. Strong evidence
Figure 2. Inflammation, endothelial dysfunction, and atherosclerosis in cardiovascular disease.
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indicates the direct association between inflammation and hypertension; TNF-α can exert vascu-
lar endothelial damage and oxidative stress, while IL-6 enhances the arterial tonus. Not only
blood pressure itself but also arterial inflammation is more prevalent in patients with RA and
independently associated with both traditional cardiovascular risk factors and rheumatoid
arthritis disease characteristics [1, 16].
There is no clear data suggesting the relation between hypertension and RA activity. However,
the deleterious role of NSAIDs and glucocorticoids on hypertension is well established [1, 16].
2.2.1.3. Insulin resistance
Although underdiagnosed, especially in RA with longer disease duration, the prevalence of
impaired fasting glucose, type 2 diabetes, as well as abnormal insulin resistance is largely incre-
ased among patients with autoimmune joint conditions compared to age- and gender-matched
CV risk factors Prevalence and particularities in RA Relation with RA activity
Tobacco smoking High prevalence in RA population
String association with CV outcome
Direct link with
• seropositivity (ACPA, RF)
• RA severity and activity
• disability
• articular damage
May impair therapeutic response, modulating
inflammation effects on CV risk
Hypertension High prevalence (COMORA 40%)
Associated with NSAIDs and DMARDs
increased vascular peripheral resistance
interplay between inflammation and hypertension
• TNFα results in endothelial vascular damage
& oxidative stress
• IL-6 alter the arterial tonus
Without evidence
Adversely impact with NSAIDs and
glucocorticoids
Insulin resistance High prevalence in RA
Promote low-grade chronic inflammation
Irrespective of RA activity
Body mass index &
obesity
Paradoxical relation in RA: low body mass index
associated with high CA risk
Body mass index—independent CV risk predictor
Relation obesity—inflammation via adipose tissue
metabolism
Irrespective of RA activity
Dyslipidemia Not only the quantity but also the quality, structure,
and function of lipids
55–65% cases—abnormal lipid profile
Lipid paradox (low lipids in inflammation
associated with high CV risk)
LDL-, HDL-, total cholesterol negatively correlates
with inflammatory biomarkers
Inflammation = consumption + decreased
lipoprotein synthesis + defect of lipoprotein
synthesis + structural and functional changes
(altered HDL)
HDL cholesterol and atherogenic index
improvement following non-biologic and
biologic DMARDs
Table 1. Traditional cardiovascular risk factors in RA.
Newest Updates in Rheumatology90
controls [1, 13, 18–20]. In addition, the link between diabetes and chronic low-grade inflammation
[1–3] is well known, supporting the hypothesis of the interaction between traditional CV risk
factors and inflammatory burden in determining diabetes in RA [1, 2, 13, 18–20]. Furthermore,
both classic risk factors (e.g., high blood pressure, high body mass index, high total cholesterol,
metabolic syndrome) and novel cardiovascular risk factors (RA duration, exposure to glucocorti-
coids, radiographic damage, CRP levels) significantly correlated with glucose metabolism abnor-
malities and diabetes [1, 2, 13, 18–20].
2.2.1.4. Body mass index and obesity
While in general, non-RA population, body mass index is recognized as an independent
predictor for cardiovascular disease, patients with RA are characterized by the paradoxical
relation obesity (cardiovascular risk): low body mass index correlates with high cardiovascular
events, unrelated to disease activity [1, 2, 6]. Moreover, the relation obesity-inflammation via
adipose tissue metabolism is largely applicable in RA patients.
2.2.1.5. Dyslipidemia and lipid paradox in RA
Abnormal serum lipid pattern remains one of the main risk factors for cardiovascular morbid-
ity and mortality in general population [1]; overall, modifications in high-density lipoprotein
(HDL)-cholesterol as well as total/ HDL-cholesterol and triglyceride/HDL-cholesterol ratios
are associated with adverse cardiovascular disease risk [1, 20].
Up to 65% of RA patients display an altered lipid profile [1, 2, 11, 12, 20], comprising modifi-
cations in absolute circulating lipid levels that widely reflect the interconnection between
inflammatory and metabolic pathways [1, 2, 20].
The well-known lipid paradox, meaning low serum concentration of lipids associated with
high cardiovascular burden in autoimmune inflammatory conditions, accounts for a negative
correlation between total cholesterol, high-density and low-density lipoprotein (LDL)-choles-
terol fractions, and inflammatory biomarkers.
Additionally, chronic inflammation is characterized by excessive consumption and deleterious
synthesis of lipoproteins associated with structural (e.g., HDL associated with increased serum
amyloid A with a potentially proatherogenic phenotype) as well as functional modifications
(e.g., altered HDL phenotype) [1, 20].
Generally, both HDL-cholesterol and LDL-cholesterol are decreased in active RA and may
increase with efficient control of inflammation with to non-biologic and biologic drugs [1, 2,
6, 20]. Moreover, small-dense LDL particles, known as more atherogenic than larger particles,
are raised not only in metabolic disorders but also in RA [1, 20].
Interestingly, preclinical phase of RA accounts for raised inflammatory biomarkers (CRP) and
dyslipidemia, with a negative correlation between the increased inflammation and decreased
serum lipids [1, 2, 20]. This paradigm is applicable not only for chronic systemic autoimmune
joint pathology but also in cardiovascular disease, postsurgery, or related to antineoplastic
therapy [1, 2, 6, 20].
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Tight control of inflammation in RA by non-biologic and/or biologic antirheumatic medication
usually accounts for the improved lipid level [1, 2, 6, 7].
2.2.2. RA activity and cardiovascular risk
Individual inflammatory parameters (erythrocyte sedimentation rate, ESR, and CRP), compos-
ite scores reflecting disease activity (such as disease activity score (DAS28) and clinical disease
activity index (CDAI)), and disease severity (extra-articular disease) are commonly associated
with cardiovascular complications in RA [1, 2, 22–28].
The link between systemic inflammation and cardiovascular outcomes persists even after
adjusting according to classical risk factors (obesity, hypertension, hyperlipidemia) [1, 2, 20–22].
Thus, elevated CRP levels at the baseline and the duration of uncontrolled disease correlate
with cardiovascular burden in RA [1, 2, 22–28], while very high disease activity over time or
high disease activity at RA onset also contributes to the cardiovascular risk [22, 23]. Moreover,
it seems that uncontrolled high disease activity promotes the highest risk of developing
cardiovascular disease [1, 2, 21–28]. CRP also correlated with acute myocardial infarction, one
of the central complications of early accelerated atherosclerosis in RA [1, 22, 23].
Clearly, low disease activity (DAS28 < 3.2) and remission (DAS28 < 2.6) are fundamental in
preventing a 10-years risk of cardiovascular events (particularly fatal or nonfatal cases of
cardiovascular disease) in RA [1, 22, 23, 29]. In fact, it seems that low stable disease activity is
able to reduce the cardiovascular burden and is appropriate to attain a protective effect against
cardiovascular disease in RA [1, 22, 23]. Similarly, clinical remission or the absence of inflam-
mation may be associated with a reduced risk of cardiovascular disease in RA [1, 22, 23];
apparently, remission has no additional protective effect against cardiovascular risk profile
compared with low disease activity [1, 2, 22, 23].
Thus, it becomes clear that the manipulation of inflammatory response and tight disease
control [22, 23, 28] are able to prevent cardiovascular events in RA [3, 26].
2.3. Cardiovascular risk assessment in RA
Different scores designed for the calculation of cardiovascular risk in general population (e.g.,
Framingham, SCORE, QRISK) underestimate the cardiovascular burden in patients with
inflammatory rheumatic conditions, mainly RA [1, 2, 6, 29, 30]; thus, there is no standard or
validated model for cardiovascular risk prediction in RA.
In EULAR 2009 has proposed to multiply by 1.5 points the SCORE risk for patients with RA if
two out of three RA-related parameters are present: a disease duration more than 10 years,
rheumatoid factor or ACPA positivity, and severe extra-articular manifestations [2, 6, 29, 30].
Despite good reliability, this score is not able to reclassify patients with RA in the adequate
cardiovascular risk category [2, 6].
QRESEARCH Cardiovascular Risk Algorithm (QRISK) 2 is a prediction model including RA
as a specific risk factor, multiplying with 1.4; it overestimates both nonfatal and fatal cardio-
vascular events [2, 6, 29, 30].
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EULAR 2016 has recommended the use of a modified SCORE adapted for patients with RA,
meaning SCORE multiplied by 1.5 irrespective of disease duration, seropositivity, or the
presence of systemic features [2, 6, 29, 30].
According to EULAR recommendations [6], the assessment of RA patients should be adapted
based on CV risk stratification and several individual factors such as change of specific anti-
rheumatic medication [2, 6, 29, 30]. Thus, risk monitoring is warranted once every 5 years if the
risk is low to moderate or more often if the patient has an intermediate and high risk or when
adapting the therapeutic protocol [2, 6]. An interesting algorithm was recently adapted/ pro-
posed by Gualtierotti et al. (Figure 3) [2].
2.4. Recommendations for cardiovascular risk assessment in RA
Cardiovascular risk stratification and further monitoring based on the risk class is essential in
RA [1, 2, 6, 29, 30]. EULAR 2009 guidelines have proposed the assessment of the cardiovascu-
lar disease on an annual basis, except for patients classified as low risk or low disease activity
where the risk is typically monitored as 2–3 years [1–3, 6].
Updated EULAR 2016 guidelines released four new recommendations emphasizing the inter-
val, scores, and protocol for cardiovascular disease screening [6]. Interestingly, cardiovascular
risk assessment is no longer recommended annually but every 5 years or following a major
change in the DMARD therapy (recommendation 2) [6]. Either local or national guidelines or
SCORE are equally accepted for the calculation of CV risk (recommendation 3) [6]. Lipid
profile comprising total cholesterol and its HDL fraction should be evaluated during stable
Figure 3. Algorithm for cardiovascular risk assessment in RA (adapted from Gualtierotti [4]).
Cardiovascular Safety of Anti-TNF and Non-TNF Biological Therapy in Patients with Rheumatoid Arthritis
http://dx.doi.org/10.5772/intechopen.76684
93
disease or remission (recommendation 4) [6]. Finally, surrogate biomarkers for subclinical
atherosclerosis such as plaques on Doppler carotid ultrasound are recommended for the
extensive screening of the cardiovascular disease in RA patients [6].
Recommendations for the management of CV risk in RA take into account three essential points
[1, 2, 6, 14]: (i) control of disease activity meaning early diagnosis and dynamic choice of the
antirheumatic drug starting with non-biologic DMARDs followed by biologic DMARDs, with or
without glucocorticosteroids until reaching the therapeutic target (remission or low disease
activity), (ii) non-pharmacological management of risk factors including smoking cessation,
adequate level of physical activity, as well as healthy diet, (iii) pharmacological management of
risk factors comprising statins for lipid abnormalities, antihypertensives, antidiabetics, etc.
Optimized disease control within the so-called treat-to-target (T2T) strategy consistently
improves the cardiovascular risk in RA, as remission and low disease activity become
realistic goals [1, 2, 4, 6, 7]. Recent advances in the pathobiology of the disease and the link
between inflammation, RA disease activity, and cardiovascular issues have highlighted the
following [1, 2, 6, 7]: (i) disease duration is not an independent cardiovascular risk factor; (ii)
disease activity, the number, and duration of flares significantly alter the CV risk; (iii)
reducing inflammation obviously improves the CV outcomes; and (iv) long-term DMARD
therapy results in lowering the CV risk.
Not only chronic persistent systemic as well as local inflammation and RA disease activity
endorse excessive cardiovascular burden in RA but also traditional CV risk factors, e.g., body
mass index, lipids, gender, tobacco smoking, and hypertension [1–3, 6].
Aggressive T2T approach in daily clinical practice for patients with RA proved successful in
negatively impacted systemic and synovial inflammation, impair cytokine release, and pro-
mote quantitative and qualitative lipid changes, significantly decreasing the cardiovascular
disease in such patients [1, 2, 6, 7]. Conversely, anti-inflammatory drugs (e.g., not only
NSAIDs and COX-2 inhibitors but also steroids) are commonly associated with high cardio-
vascular safety issues [1, 2, 6].
Regardless of substantial progresses in RA treatment, patients develop and die considerably
earlier than the general population mainly related to cardiovascular comorbidities, generally in
connection with accelerated atherosclerosis and cardio-metabolic complication [1, 2, 13, 18, 21].
2.5. 2016 EULAR recommendation for CV management
Since broad cardio-metabolic evaluation and optimal strategies for cardiovascular risk reduc-
tion are still poorly integrated in routine practice in autoimmune conditions [13, 18, 21],
EULAR has recently updated guidelines for cardiovascular disease risk assessment and man-
agement in systemic inflammatory conditions including RA, psoriatic arthritis, and ankylosing
spondylitis [6]. An extended EULAR task force has reconsidered the old guidelines and
released new overarching principles and recommendations in accordance to PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-analysis) statement suggesting an
appropriate algorithm for cardiovascular risk management in these patients [6].
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Updated EULAR 2015/2016 guidelines for cardiovascular comorbidity in RA are listed below [6]:
1. Lowering the cardiovascular risk in RA largely relies on both early diagnosis and tight
control of disease activity as well as the disease flares.
2. The cardiovascular risk reassessment is advised at least every 5 years or when major
changes in DMARD therapy are specified.
3. EULAR endorses the application of risk assessment scores according to the general popu-
lation such as systematic coronary risk evaluation (SCORE) or national guidelines for CVD
risk evaluation.
4. A systematic evaluation of lipid profile including non-fasting total cholesterol and low-
and high-density lipoprotein fractions is mandatory to further mitigate the cardiovascular
risk; however, measurements should be achieved during stable RA or in remission disease.
5. A correct estimate of the increased risk of cardiovascular events in RA encompasses for a
modified risk score multiplied by 1.5.
6. Surrogates of subclinical atherosclerosis and cardiovascular disease such as artery plaques
identified by carotid ultrasound screening are useful to perceive the increased cardiovas-
cular risk in RA.
7. Several protective measures, e.g., healthy diet, exercise on a daily basis, and smoking cessa-
tion, should underline the general approach of RA patients with raised cardiovascular risk.
8. New trends in treating hypertension and dyslipidemia with specific medication including
antihypertensives and statins are widely recommended in patients with RA with such
comorbidities.
9. Since both traditional nonselective NSAIDs and coxibs have an increased risk of develop-
ing cardiovascular toxicity in RA, these drugs are carefully proposed in such patients,
especially in those with prior history of or at increased risk to develop further cardiovas-
cular events (congestive heart failure, ischemic heart disease, peripheral arterial or cere-
brovascular disease).
10. If mandatory, long-term corticosteroids are managed to minimize the total dosage, with
tapering as soon as remission or low disease activity is reached.
3. Cardiovascular safety of non-biologic and biologic anti-rheumatic drugs
Evidence-based medicine provides key insights into the consequences of various classes of
antirheumatic drugs on cardiovascular risk in RA, suggesting that TNF inhibitors (TNF-i) and
methotrexate decrease the risk of such events, while corticosteroids and IL-6 receptor inhibi-
tion via tocilizumab exert a multifaceted intervention on cardiovascular outcomes [1, 2, 26, 31].
Data are summarized in Table 2.
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3.1. Non-biologic DMARDs: methotrexate and non-methotrexate drugs (e.g., sulfasalazine,
antimalarials, leflunomide) improve cardiovascular outcomes in RA
Recent meta-analysis as well as real-life data showed that traditional synthetic DMARDs are
able to reduce the cardiovascular risk in RA. However, the precise cardioprotective mechanism
of classic immunosupressants remains still under debate.
Undoubtedly, methotrexate and non-methotrexate agents efficiently control inflammation and
disease activity, alter the lipid spectrum and concentration, and are able to reduce the arterial
stiffness, improving cardiovascular risk in different RA scenarios [1–32].
Furthermore, methotrexate, the drug of choice as first-line treatment, is associated with a
consistent reduction in mortality (70%), a decline in the rate of total cardiovascular events
(around 28%), and up to 18% lower risk of myocardial infarction in patients with RA [31].
Unlike the anti-TNF agents, methotrexate is not related to a significant decrease in strokes and
major adverse cardiac events; nevertheless, it seems that the risk of heart failure is also
decreased [1, 2, 31, 32].
The interesting hypothesis of inflammatory origin of cardiovascular disease prompted the
ongoing randomized Cardiovascular Inflammation Reduction Trial (CIRT) aiming to investi-
gate whether low-dose methotrexate is able to decrease rates of heart attacks, strokes, and
cardiovascular death among stable coronary artery disease patients with type 2 diabetes and/
or metabolic syndrome, conditions associated with an enhanced pro-inflammatory response
[3]. Although the study was designed to perceive a 25% cardiovascular risk decline within the
Drug Positive effects Negative effects Overall influence
on CV safety
Methotrexate Improved RA activity High homocysteinemia Protective
Other
csDMARDs
Leflunomide
Antimalarials
Improved RA activity, improved lipid
profile, reduced risk of diabetes
Arterial hypertension
May be responsible of
cardiomyopathy although rarely
Complex effect
Protective
TNF inhibitors Improved RA activity, reduced insulin
resistance
Contraindicated in severe heart
failure (class III/IV NYHA)
Protective
Non-TNF
inhibitors
Tocilizumab
Rituximab
Abatacept
Tofacitinib
Improved RA activity
Safe in heart failure
Safe in heart failure
Safe in heart failure
Abnormal lipids Complex effect
Complex effect
Complex effect
Corticosteroids
NSAIDs
Reduced inflammation May increase CV events, BMI,
dyslipidemia, insulin
resistance, hypertension
All NSAIDs increase CV risk
(prothrombotic effect)
Complex effect
Table 2. Cardiovascular profile of anti-rheumatic drugs: non-biologic and biologic DMARDs, corticosteroids, NSAIDs.
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methotrexate group, failure to achieve this magnitude of risk reduction will not degrade the
immune inflammatory background of cardiovascular pathology [3].
Data about other synthetic DMARDs are not consistent. Leflunomide has indirect positive
effects on cardiovascular outcome through reducing disease activity, while its role in promot-
ing hypertension is a potential limitation, particularly if high blood pressure is documented
[1, 2]. Antimalarials, specifically hydroxychloroquine, are able to modulate lipid profile and to
reduce the risk of diabetes, although rare cases of cardiomyopathy have been described [1, 2,
31, 33]. Finally, sulfasalazine seems to exert also protective effects, while further studies are
required to clearly define its role [2].
3.2. Glucocorticoids enhance the cardiovascular risk in RA
The association between corticosteroids and the rate of total as well as individual cardiovascu-
lar events was systematically evaluated in patients with inflammatory rheumatic disorders,
principally in RA and systemic lupus. It is widely accepted that corticosteroids are able to
shape the cardiovascular risk by two competitive pathways [1, 2, 6, 31, 34]:
• The risk for future cardiovascular disease is increased due to not only metabolic effects,
e.g., abnormal lipid metabolism, impaired glucose tolerance, insulin resistance, relative
weight gain, or true obesity, but also glucocorticoid-induced hypertension.
• The cardiovascular risk is attenuated through rapid and salutary anti-inflammatory and
anti-proliferative effects of corticosteroids.
Their cardiotoxicity as well as cardiovascular mortality is dose-dependent (actual and previous
cumulative dose) [1, 2, 6]. Sustained administration of corticosteroids classically accounts not
only for an increased risk of myocardial infarction, stroke, and congestive heart failure but also
for all major adverse cardiac events in RA patients as suggested by different studies and meta-
analyses [1, 2, 6, 31, 34].
The well-known trend in RA is to maintain the lowest dose of corticosteroids for the shortest
period of time and tapering as soon as remission or low disease activity (recommendation 10,
EULAR 2016) [6]; the benefits of further administration should be deliberated and reconsi-
dered once the disease outcomes have been achieved [6].
Although NSAIDs no longer represent the mainstay of RA therapeutic protocol, both
nonselective and COX2-selective medications are still used, even if intermittently, during RA
flares and in short-time administration [1, 2, 22, 23, 31, 35]. NSAID safety profile should be
emphasized, as their effect on cardiovascular outcomes in RA is challenging. Both nonselective
NSAIDs and coxibs increase the cardiovascular risk in general population; however, not all of
them exert the same deleterious cardiovascular effect, especially talking about patients with
RA [2, 6, 31, 35].
It is widely recognized that long-term NSAIDs increased the risk of all cardiovascular events
and stroke in general population, particularly if cardiovascular disease is documented (con-
gestive heart failure, ischemic heart disease, peripheral arterial disease, or cerebrovascular
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disease) [2, 6, 31]; only few studies have addressed the cardiovascular outcomes of COX2-
selective and traditional NSAIDs specifically in RA [1, 2, 6, 31, 35].
3.3. Biologic DMARD: TNF inhibitors decrease the cardiovascular risk in RA
TNF-α, a pivot pro-inflammatory cytokine involved in both systemic and local (synovial
microenvironment) persistent inflammations in RA, may also alter lipid metabolism, insulin
resistance, and endorse endothelial dysfunction [1, 2, 6, 31, 36, 37]. Moreover, chronic inflam-
mation and atherosclerosis share common pathways, tailoring the basis of amplified cardio-
vascular risk in inflammatory rheumatic conditions [1, 2].
On the other hand, TNF inhibitors provide multifaceted influences on cardiovascular safety in
patients with RA comprising [1, 2, 6, 31, 37]:
• Rapid and effective control of chronic inflammation signaling with significant decrease in
inflammatory parameters (serum CRP levels and ESR), RA activity, and delay articular
damage articular
• Changes in lipid pattern with increase in HDL-cholesterol fraction, total cholesterol, tri-
glycerides with or without influence on LDL-cholesterol fraction, and with no major impact
on the atherogenic index (TC/HDL); in fact, the trend of rising serum lipids under anti-TNF
therapy typically reflects the stabilization through the lipid levels before the RA onset
• Improvement of endothelial dysfunction and insulin sensitivity as well as the anti-
oxidative response of HDL
Thus, it seems that TNF inhibitors are efficient in reducing cardiovascular comorbidities in RA,
comprising not only all cardiovascular events but also some specific stroke, myocardial infarc-
tion, and even MACE [1–3, 31, 36, 37].
A meta-analysis of several observational studies and registries in RA patients treated with TNF
inhibitors performed by Roubille et al. showed a significant reduction in the risk of all cardio-
vascular events (up to 30%), myocardial infarctions, strokes, and major adverse cardiac events
with biologics vs. non-biologic DMARDs [1–3, 31, 36, 37]. However, no significant effect on
heart failure was detected [2, 31]. Interestingly, the risk of future cardiovascular consequences
under anti-TNF medication is twice lower that the risk with non-biologic non-methotrexate
drugs [1–3, 31, 36, 37].
Besides, Ljung et al. recently published their study investigating the effects of response to anti-
TNF agents on short-term (1- and 2-year follow-up) risk of acute coronary syndrome in
individuals with active RA and no previous ischemic or congestive heart disease before
starting TNF-i as the first biologic agent [37].
RA patients classified as good (but not moderate) EULAR responders (improvement of more
than 1.2 points in disease activity score) to anti-TNF therapy showed a 50% risk reduction of
acute myocardial infarction or unstable angina pectoris or acute myocardial infarction as the
underlying cause of death in short-term follow-up, similarly to the risk of acute coronary
events in general population [1, 2, 6, 31, 36, 37].
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In fact, the magnitude of coronary event risk reduction was reported irrespective of the
baseline risk stratification (by gender, age, cardiovascular risk factors, disease duration), drug
exposure, as well as the risk window [2, 31, 36, 37]. Additionally, the ability to achieve optimal
control of RA activity instead of simply improved disease control or TNF-i per se theoretically
stabilizes the pattern of ischemic heart disease in RA [1–3, 31, 36, 37].
Still considered the “black box” of TNF biologic class, the link between TNF blockade and
moderate to severe congestive heart failure (class III/class IV NYHA) remains controversial [1,
2, 31, 36]. Clearly, heart failure in general population is associated with high TNF-α, with
consistent correlation between serum levels and clinical significance and severity of cardiac
failure [1, 31, 36]. However, TNF inhibitors are able to improve ventricular dysfunction in
experimental models of cardiac failure [1, 2, 6, 31, 36, 37].
Overall, TNF inhibitors significantly damper the cardiovascular comorbidity in RA, especially
in patients declared responders to such therapies.
3.4. Non-TNF DMARDs: tocilizumab
Data about tocilizumab, a humanized monoclonal antibody acting against the IL-6 receptor
(membrane-bound and soluble), and its cardiovascular toxicity are widely accessible from
different clinical trials, including ADACTA, TOWARD, MEASURE, and ENTRACTE [38–41].
Although modest increases of LDL- and HDL-cholesterol as well as triglycerides were noticed
in RA patients treated with tocilizumab in randomized controlled trials, only ENTRACTE was
specifically designed to evaluate the cardiovascular safety and to compare net cardiovascular
risk-benefit ratio of anti-IL-6 therapy with biologics with another mechanism of action, such as
etanercept, in active seropositive RA [1, 2, 38–41].
As a potent inhibitor of IL-6 signaling, tocilizumab is associated with excellent clinical efficacy
essentially related to patent decline in systemic inflammatory biomarkers; in addition,
tocilizumab-associated altered lipid profile, mainly increased LDL-cholesterol, is broadly rec-
ognized and potentially connected with atherogenesis and atherothrombosis in patients with
RA [1, 2, 3, 39–42].
Moderate elevations of LDL-cholesterol, HDL-cholesterol, and triglycerides were faced in RA
patients under tocilizumab in phase II and phase III trials, but the atherogenic implications of
these changes are still unsettled [1, 2, 38–41].
A summary of trials reflecting the cardiovascular safety profile of tocilizumab in RA comprises
the following:
ADACTA, a randomized clinical trial to evaluate tocilizumab monotherapy vs. adalimumab
monotherapy for the treatment of RA, suggested that tocilizumab meaningfully decreases
systemic inflammation as supported by low ESR and CRP levels and disease activity (DAS28,
CDAI). Changes are obviously more evident as compared to adalimumab, a totally humanized
monoclonal anti-TNF antibody; however, tocilizumab induces higher LDL-cholesterol levels
more than adalimumab do [39].
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TOWARD trial, evaluating tocilizumab in combination with traditional DMARD therapy,
revealed the role of IL-6 blockade not only in reducing articular and systemic inflammation
but also in improving insulin resistance, along with its capacity to promote increased total
cholesterol levels in up to one-fourth of cases [38].
Tocilizumabmay induce particular changes in lipid pattern,with potential relevance for cardiovas-
cular safety. Persistent increase in mean fasting plasma lipids, within the normal range, is com-
monly reported with tocilizumab, together with a consistent decrease in serum CRP, suggesting
that abnormal lipid levels may, in part, be related to significant decline in inflammation [38].
An increase in total cholesterol was observed in one out of five RA included in the study, while
high LDL and altered HDL status from a pro-inflammatory to a significantly low inflamma-
tory status (12 and 15%, respectively) increases of 30% in the total cholesterol:HDL-cholesterol
ratio (12% cases) and more frequent in the LDL-cholesterol:HDL-cholesterol ratio (20%) were
also reported. Finally, increases in the mean apolipoprotein A-I and apolipoprotein B, within
the normal range, without changes in the ApoB:ApoA-I ratio were also commonly described.
Only a limited number of patients initiated statin therapy during the study, with positive
influence on lipid modifications [38].
MEASURE trial of tocilizumab effects on surrogates of vascular risk in RA was powered to
demonstrate the modulation of lipid and lipoprotein particle (LDL, HDL, VLDL) levels and
composition (HDL-associated serum amyloid A), alongside other surrogates of vascular risk
(markers of coagulation, thrombosis, and vascular function) with IL-6 receptor inhibition vs.
placebo in active disease [40, 41].
McInnes et al. [41] not only reported a dramatic decrease in inflammation in such patients but
also demonstrated quantitative and qualitative changes in lipid metabolism profile. Overall,
tocilizumab prompted the increase in total cholesterol, LDL-cholesterol, and triglycerides by
week 12 of administration, while no significant influence on proatherogenic small LDL particle
concentration, oxidized (ox)LDL, or HDL-cholesterol levels, in addition to ApoB:ApoA-1 ratio.
Furthermore, tocilizumab-based IL-6 signal blockade altered the HDL particle composition
toward a less pro-inflammatory phenotype [40, 41].
Besides, HDL-associated serum amyloid A, secretory phospholipase A2-IIA, lipoprotein(a),
fibrinogen, and D-dimers presented a sizeable decrease, while the antioxidant enzyme associ-
ated with HDL, paraoxonase, and level significantly increased under tocilizumab. Since a
prothrombotic status heightened risk for cardiovascular events independently of established
risk factors in general population, the reduction of thrombotic potential with tocilizumab in
patients with active RA remains of considerable interest [40, 41].
However, the clear benefit of such modifications for cardiovascular risk is still debatable.
ENTRACTE, a randomized clinical trial aiming to evaluate cardiovascular events with either i.
v. tocilizumab monthly or etanercept s.c weekly, was designed as a non-inferiority study
comparing cardiovascular safety of tocilizumab vs. the TNF receptor, etanercept, in RA. Pri-
mary endpoint focused on major cardiovascular adverse events (MACE) (cardiovascular
death, nonfatal myocardial infarction, nonfatal stroke), while secondary endpoints were car-
diovascular and non-cardiovascular safety of both drugs [1–3].
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ENTRACTE has demonstrated a relative increase in the incidence of cardiovascular events
among severe active RA patients with a background of cardiovascular risk factors receiving
tocilizumab, specifically the hazard of MACE. Additionally, the average level of LDL-
cholesterol was consistently higher under tocilizumab as compared with etanercept. Neverthe-
less, the cardiovascular issues with tocilizumab vs. etanercept should be deliberated/
interpreted in the context of its clinical efficacy and general, non-cardiovascular, safety profile.
3.5. Other non-biologic and targeted DMARDs: rituximab, abatacept, and tofacitinib
• Rituximab, a B-cell depletory agent, typically indicated as a second-line biologic therapy
after failure of at least one anti-TNF agent, showed no significant differences as compared
to placebo in terms of cardiovascular events. There is no cardiovascular safety concern
related to rituximab; furthermore, it seems that rituximab is able to improve lipid metab-
olism, alter HDL-cholesterol to a low atherogenic profile, as well decrease prothrombotic
biomarkers. Also, rituximab has no influence on arterial stiffness [1–3, 6, 7, 42].
• Abatacept, by blocking the T and B costimulation, commonly acts on lipid pattern
resulting in high total cholesterol and its fractions (HDL-cholesterol and LDL-cholesterol),
without a significant decrease in the atherogenic index; however, abatacept is known to
alter the arterial tonus [1–3, 6, 7].
• Tofacitinib, a JAK inhibitor already approved for the management of RA, promotes similar
changes in lipid profile as tocilizumab do, meaning an increase of both HDL-cholesterol and
LDL-cholesterol, with a minimal impact on atherogenic index [1–3, 6, 7, 43].
4. Conclusions
Systemic autoimmune rheumatic conditions, specifically RA, are widely associated with exces-
sive cardiovascular morbidity, with a magnitude similar to that related to traditional cardio-
vascular risk factors, particularly diabetes.
A multifaceted dynamic interplay between chronic systemic inflammation, RA-specific issues,
early accelerated atherosclerosis, and classic cardiovascular risk factors typically highlights the
cardiovascular burden in various RA settings.
The optimal strategy to identify patients at increased risk to develop cardiovascular disease as
well as the correct assignment of different risk categories is mandatory in routine practice in
every RA case. Furthermore, the selection of suitable medication (non-biological, TNF inhibi-
tor, or non-TNF biological antirheumatic drug) according to cardiovascular toxicity is
warranted so as to improve cardiovascular outcomes in RA.
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